Lexicon Pharmaceuticals Receivables

Lexicon Pharmaceuticals (LXRX) currently reports a receivables of $12M as of March 2026. That compares with $47M in the prior-year period — down 75.2% year over year. Use the charts on this page to explore Lexicon Pharmaceuticals's receivables history and peer comparisons.

Lexicon Pharmaceuticals's receivables decreased from $47M to $12M — a 75.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lexicon Pharmaceuticals reported $12M in receivables as of March 2026. That compares with $47M in the prior-year period — down 75.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lexicon Pharmaceuticals, and consider following LXRX for alerts when major investors trade the stock.

Lexicon Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $12M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LXRX with unrelated industries.